CN108884123A - 抑制癌症及病毒的化合物 - Google Patents

抑制癌症及病毒的化合物 Download PDF

Info

Publication number
CN108884123A
CN108884123A CN201780006499.9A CN201780006499A CN108884123A CN 108884123 A CN108884123 A CN 108884123A CN 201780006499 A CN201780006499 A CN 201780006499A CN 108884123 A CN108884123 A CN 108884123A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutically acceptable
tautomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780006499.9A
Other languages
English (en)
Chinese (zh)
Inventor
阎云
刘景平
刘韵如
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taipei Medical University TMU
Original Assignee
Taipei Medical University TMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taipei Medical University TMU filed Critical Taipei Medical University TMU
Publication of CN108884123A publication Critical patent/CN108884123A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780006499.9A 2016-01-12 2017-01-12 抑制癌症及病毒的化合物 Pending CN108884123A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277653P 2016-01-12 2016-01-12
US62/277,653 2016-01-12
PCT/US2017/013253 WO2017123809A1 (en) 2016-01-12 2017-01-12 Compounds for inhibiting cancer and virus

Publications (1)

Publication Number Publication Date
CN108884123A true CN108884123A (zh) 2018-11-23

Family

ID=59311465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780006499.9A Pending CN108884123A (zh) 2016-01-12 2017-01-12 抑制癌症及病毒的化合物

Country Status (7)

Country Link
US (1) US10745433B2 (https=)
EP (1) EP3402800A4 (https=)
JP (1) JP2019506382A (https=)
CN (1) CN108884123A (https=)
CA (1) CA3011289A1 (https=)
TW (1) TWI638825B (https=)
WO (1) WO2017123809A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518147A (zh) * 2020-04-29 2020-08-11 华东理工大学 苯甲酰苯胺类化合物及在制备铜绿假单胞菌抑制剂的增敏剂中的应用
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223491A1 (en) * 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
US11767303B2 (en) 2020-07-24 2023-09-26 Health Research, Inc. Compounds and methods for inhibiting viral replication and methods of treating and preventing flaviviral infections

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD150471A1 (de) * 1979-07-02 1981-09-02 Konrad Schwabe Verfahren zur herstellung von 5-bromsalizyl-4'-chloranilid-0-glykosiden
WO2001074835A1 (en) * 2000-03-30 2001-10-11 Bristol-Myers Squibb Company O-glucosylated benzamide sglt2 inhibitors and method
US20070123493A1 (en) * 2003-12-26 2007-05-31 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
CN103130696A (zh) * 2013-03-21 2013-06-05 山东大学 邻氨基苯甲酰胺类化合物及其制备方法与应用
WO2014113467A1 (en) * 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE150471C (https=) *
CA2488363C (en) * 2002-06-06 2011-01-04 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
ES2647072T3 (es) 2011-04-18 2017-12-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Niclosamida para el tratamiento de la metástasis en el cáncer
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN104771386A (zh) 2014-01-10 2015-07-15 中国科学院广州生物医药与健康研究院 苯甲酰胺类化合物及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD150471A1 (de) * 1979-07-02 1981-09-02 Konrad Schwabe Verfahren zur herstellung von 5-bromsalizyl-4'-chloranilid-0-glykosiden
WO2001074835A1 (en) * 2000-03-30 2001-10-11 Bristol-Myers Squibb Company O-glucosylated benzamide sglt2 inhibitors and method
US20070123493A1 (en) * 2003-12-26 2007-05-31 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2010101648A1 (en) * 2009-03-06 2010-09-10 Wood Richard D Glutamate receptor modulators and therapeutic agents
WO2014113467A1 (en) * 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
US20150361031A1 (en) * 2013-01-15 2015-12-17 Board Of Regents, The University Of Texas System Stat3 inhibitor
CN103130696A (zh) * 2013-03-21 2013-06-05 山东大学 邻氨基苯甲酰胺类化合物及其制备方法与应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN111518147A (zh) * 2020-04-29 2020-08-11 华东理工大学 苯甲酰苯胺类化合物及在制备铜绿假单胞菌抑制剂的增敏剂中的应用

Also Published As

Publication number Publication date
EP3402800A4 (en) 2019-11-13
WO2017123809A1 (en) 2017-07-20
TW201734028A (zh) 2017-10-01
EP3402800A1 (en) 2018-11-21
CA3011289A1 (en) 2017-07-20
TWI638825B (zh) 2018-10-21
JP2019506382A (ja) 2019-03-07
US10745433B2 (en) 2020-08-18
US20190016743A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CN116096372B (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
CN108366979B (zh) 与泛素化－蛋白酶体系统有关的化合物及医药组合物
CN108884123A (zh) 抑制癌症及病毒的化合物
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
CN110357897A (zh) 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用
US11267815B2 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
TW201625313A (zh) 新穎麩胺酸衍生物及其用途
CN117062819A (zh) 多环化合物及其用途
JP2022550489A (ja) スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用
CN105732643A (zh) 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
TWI684581B (zh) 與泛素化-蛋白酶體系統有關之化合物及醫藥組合物
CN111377925A (zh) 嘌呤类衍生物、其制备方法及其在医药上的应用
US11008293B2 (en) 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments
KR102436669B1 (ko) 우레아-치환된 방향족 고리-연결된 디옥시노퀴놀린 화합물 및 이의 제조방법 및 용도
CN111171041B (zh) 20位取代的喜树碱衍生物及其制备方法和应用
HK40065458A (en) Kras g12c inhibitor and pharmaceutical use thereof
WO2025250128A1 (en) Cyproheptadine derivatives
WO2022162025A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
WO2024188302A1 (zh) 一类靶向端粒酶的核苷类似物及其应用
WO2019134082A1 (en) Novel pyrimidine derivatives as mth1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123